JPMorgan analyst David Adlington lowered the firm’s price target on Medacta Group to CHF 93 from CHF 100 and keeps a Neutral rating on the shares.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MEDGF: